## Atomic Force Microscopy analysis of native infectious and inactivated SARS-CoV-2 virions

Sébastien Lyonnais<sup>1,\*</sup>, Mathilde Hénaut<sup>1</sup>, Aymeric Neyret<sup>1</sup>, Peggy Merida<sup>2</sup>, Chantal Cazevieille<sup>3</sup>, Nathalie Gros<sup>1</sup>, Christine Chable-Bessia<sup>1</sup> and Delphine Muriaux<sup>1,2</sup>\*

## **Affiliations**

<sup>1</sup>CEMIPAI, University of Montpellier, UAR3725 CNRS, Montpellier, France

<sup>2</sup>Institute of Research in Infectiology of Montpellier (IRIM), University of Montpellier, UMR9004 CNRS, Montpellier, France

<sup>3</sup>Université de Montpellier, Institut des Neurosciences de Montpellier (INM), Montpellier, France

\*Corresponding authors: sebastien.lyonnais@cemipai.cnrs.fr, delphine.muriaux@cemipai.cnrs.fr


## SUPPLEMENTARY INFORMATION

Supplementary Figures


Figure S1. SARS-CoV-2 identification

Figure S2. AFM images of native infectious SARS-CoV-2


Figure S3. Native and inactivated SARS-CoV-2 titration followed by plaque assays



**Supplementary Figure S1.** SARS-CoV-2 identification. (a) Western Blot analysis of SARS-CoV-2 S, N and M proteins in lysates of infected (I) and non infected (NI) VeroE6 cells. (b) SARS-CoV-2 production in the cell supernatant followed by qRT-PCR targeting the E gene. (c) An example of TEM image of SARS-CoV-2 infected VeroE6 cells for 24h (MOI=0.1)



**Supplementary Figure S2.** AFM images of native infectious SARS-CoV-2 found embedded in a network of filamentous structures. (a-d) AFM topographic images of infectious native SARS-CoV-2 from cell supernatant directly adsorbed on a mica surface using QI mode AFM in buffer. Scale bars in all panels: 200 nm.



**Supplementary Figure S3**. Native and inactivated SARS-CoV-2 titration followed by plaque assays (a) Viral stock titration by 10-fold dilutions of SARS-CoV-2 specimen from  $10^{-2}$  to  $10^{-6}$ , as well as non-infected cells supernatant (NI) as a negative control. Plaques can be distinguished from the crystal violet monolayer and used for the calculation of virus titers in Plaque Formation Unit/mL (PFU/mL) (b) Virus titration after incubation of SARS-CoV-2 specimen for 30 min. at 20°C followed by 5 washes using centrifugal concentrator (red area). Undiluted virus samples incubated for 30 min. at 58°C or 30 min. at 20°C in presence of 0.5%, 1% or 2% Formaldehyde (FA), followed by 5 washes using centrifugal concentrator (black area). (c) Virus titration after virus incubation for 4h at 4°C in presence of 0.1% FA. (d) Virus recovered from ultracentrifugation after incubation for 30 min. at 20°C in absence (left panel) or in presence of 0.5% or 1% FA.